MC5R and myelodysplastic syndrome: An investigator-initiated trial study with MC5R-specific silent hematopoietic stem cell transplantation strategy, achieved by gene editing using CRISPR-Cas9 platform, will be a potential clinical advance for the ultimate cure for MDS patients.